CompletedNCT00649064
Official study titleA Multi-Center Study To Examine The Clinical Effects Of Cross Titration Of Antipsychotics With Ziprasidone In Subjects With Schizophrenia Or Schizoaffective Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including ChanghuaSchizophreniaMedication studyAges 18–65
- Countries
- Taiwan
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
CompletedNCT00650429
Official study titleZiprasidone Intramuscular/Oral In The Treatment Of Acute Exacerbation Of Schizophrenia Or Schizoaffective Disorder: A Six-Week Open Administration Study
This study has finished and is no longer accepting participants.
Multiple locations, including MonterreySchizophreniaMedication studyAges 18–70
- Countries
- Mexico
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
TerminatedNCT00645229
What is this study about?This study evaluates the safety and effectiveness of Ziprasidone for people with schizophrenia.
This study ended early.
In LisbonSchizophreniaMedication studyAges 18–60
- Countries
- Portugal
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
CompletedNCT06003036
Official study titleAccelerated Neuromodulation of Prefrontal Circuitry During Clozapine Treatment
This study has finished and is no longer accepting participants.
In PittsburghSchizophreniaDevice studyAges 18–65
- Countries
- United States
- Sponsor
- Deepak K. Sarpal, M.D.
CompletedNCT02186769
Official study titleA Randomized, Open-Label Pharmacokinetic Study of LY03004 Compared to Risperdal® Consta® Following a Single Intramuscular Injection at 25 mg or 50 mg in Stable Patients With Schizophrenia and/or Schizoaffective Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including Orange CountySchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Luye Pharma Group Ltd.
TerminatedNCT04203056
This study ended early.
In Los AngelesSchizophrenia, DepressionMedication studyAges 18–45
- Countries
- United States
- Sponsor
- University of California, Los Angeles
CompletedNCT00325689
Official study titleA Multicenter, Randomized, Double-blind, Placebo-controlled, 16 Week Study of Aripiprazole Used as Dual Therapy in the Treatment of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder Demonstrating an Inadequate Response to Quetiapine or Risperidone Monotherapy.
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockSchizophreniaMedication studyAges 18+
- Countries
- United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
CompletedNCT00796185
Official study titleComparison of Steady-state Pharmacokinetics of Paliperidone After Extended-release OROS� Paliperidone 15 mg and Immediate-release Oral Risperidone 8 mg b.i.d. in Subjects With Schizophrenia or Schizoaffective Disorder
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–50
- Countries
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT02091388
Official study titleA Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Luye Pharma Group Ltd.
CompletedNCT03708315
Official study titleSafety and Efficacy of BXCL501, a Sublingual Film Delivery of Dexmedetomidine for the Treatment of Acute Agitation in Schizophrenia
This study has finished and is no longer accepting participants.
In New HavenSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Yale University
WithdrawnNCT00672464
Official study titleCombined Treatment of Cardiovascular Risk Factors In Newly Admitted Patients With Schizophrenia or Schizoaffective Disorder Who Are Receiving Olanzapine And Matched Controls
This study was withdrawn before enrollment.
Multiple locations, including ButnerSchizophreniaMedication studyAges 18–60
- Countries
- United States
- Sponsor
- Duke University
CompletedNCT07427485
Official study titleCognitive Rehabilitation With Immersive Virtual Reality (IVR) in Schizophrenia: a Pilot Randomized Waiting List Controlled Feasibility Study
This study has finished and is no longer accepting participants.
In Torre del GrecoSchizophreniaDevice studyAges 18–67
- Countries
- Italy
- Sponsor
- Azienda Sanitaria Locale Napoli 3 Sud, UOCSM Torre del Greco